After Morgan Stanley and Guggenheim gave McKesson (NYSE: MCK) a Buy rating last month, the company received another Buy, this time from J.P. Morgan. Analyst Lisa Gill maintained a Buy rating on McKesson today and set a price target of $187.00. The company’s shares closed last Monday at $132.11.
According to TipRanks.com, Gill is a 5-star analyst with an average return of 14.7% and a 61.9% success rate. Gill covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, CVS Health, and Teladoc.
McKesson has an analyst consensus of Moderate Buy, with a price target consensus of $168.90, representing a 28.4% upside. In a report issued on March 13, Guggenheim also upgraded the stock to Buy.
See today’s analyst top recommended stocks >>
Based on McKesson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $59.17 billion and net profit of $186 million. In comparison, last year the company earned revenue of $56.21 billion and had a net profit of $469 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical and Specialty Solutions; European Pharmaceutical Solutions; Medical-Surgical Solutions and Other.
